Article

1 2

Serological Survey in a university community after the fourth wave of COVID-19 in Senegal

5

- 6 Fatou THIAM 1*, Abou Abdallah Malick DIOUARA 1, Clemence Stephanie Chloe Anoumba
- 7 NDIAYE ¹, Ibrahima DIOUF ², Khadim KEBE ¹, Assane SENGHOR ¹, Djibaba DJOUMOI ¹,
- 8 Mame Ndew MBAYE ¹, Idy DIOP ³, Sarbanding SANE ¹, Seynabou COUNDOUL ¹, Sophie deli
- 9 TENE ¹, Mamadou DIOP ¹, Abdou Lahat DIENG ², Mamadou NDIAYE ⁴, Saidou Moustapha
- 10 SALL², Massamba DIOUF⁵, Cheikh Momar NGUER¹
- 11 ¹ Groupe de Recherche Biotechnologies Appliquées & Bioprocédés Environnementaux, École
- 12 Supérieure Polytechnique, Université Cheikh Anta Diop de Dakar, Corniche Ouest BP : 5085 Dakar-
- $13 \qquad \text{Fann,} \quad \text{Senegal} \; ; \quad \underline{\text{fatou54.thiam@ucad.edu.sn}} \quad \text{(F.T.),} \quad \underline{\text{malick.diouara@ucad.edu.sn}} \quad \text{(A.A.M.D.),} \quad \underline{\text{malick.diouara@ucad.edu.sn}} \quad \text{(A.A.M.D.),} \quad \underline{\text{malick.diouara@ucad.edu.sn}} \quad \underline{\text{(A.A.M.D.)}} \; .$
- anoumbachloe@gmail.com (S.C.C.A.N.), kebe.khadim@esp.sn (K.B.), azoozeng@hotmail.com (A.S.),
- 15 <u>djibabadjoumoi@gmail.com</u> (D.D.), <u>mamendew.mbaye@esp.sn</u> (M.N.M.), <u>sarbandingsane@esp.sn</u>
- $16 \hspace{1cm} (S.S.), \hspace{0.1cm} \underline{seynaboucoundoul@esp.sn} \hspace{0.1cm} (S.C.), \hspace{0.1cm} \underline{sophiedelitene@esp.sn} \hspace{0.1cm} (S.D.T.), \hspace{0.1cm} \underline{mamadou.diop1@esp.sn} \hspace{0.1cm}$
- 17 (M.D.), <u>cmnguer@gmail.com</u> (C.M.N.)
- 18 ² Laboratoire Physique de l'Atmosphère et de l'Océan-Siméon Fongang, École Superieure
- 19 Polytechnique, Université Cheikh Anta Diop de Dakar, Corniche Ouest BP : 5085 Dakar-Fann, Dakar
- 20 10700 Senegal; <u>ibrahima23.diouf@ucad.edu.sn</u> (I.D.), <u>abdoulahat.dieng@ucad.edu.sn</u> (A.L.D.),
- 21 <u>saidou.sall@ucad.edu.sn</u> (S.M.S)
- Laboratoire d'Imagerie Médicale et de Bio-Informatique, École Superieure Polytechnique, Université
 Cheikh Anta Diop de Dakar, Corniche Ouest BP: 5085 Dakar-Fann, Senegal; idv.diop@esp.sn (I.D.)
- 24 ⁴ Laboratoire Mathématiques Appliquées et Informatique, Faculté des Sciences et Techniques,
- Université Cheikh Anta Diop de Dakar, Corniche Ouest BP : 5085 Dakar-Fann, Senegal;
- 26 mamadou1.ndiaye@unchk.edu.sn (M.N.)
- 27 ⁵ Laboratoire Sante Publique, Institut d'odontologie et de Stomatologie, Faculte de Medecine, de
- 28 Pharmacie et d'Odonthologie, Université Cheikh Anta Diop de Dakar, Corniche Ouest BP : 5085
- 29 Dakar-Fann, Senegal; massamba.diouf@ucad.edu.sn (M.D.).

30 31

* Correspondence: Email address: fatou54.thiam@ucad.edu.sn (F.T.); Tel: +221786300621

32 33

34

35

36

37 38

39

40

4142

43

4445

46

Abstract.

 Cross-sectional survey was conducted to assess the true extent of COVID-19 exposure among students and staff of Polytechnic High School (PHS). Random cluster sampling was carried out between May 19 and August 18, 2022, after the fourth wave of COVID-19 transmission. IgM and IgG SARS-CoV-2 antibodies were screened using WANTAI SARS-CoV-2 ELISA assays. Seroprevalence and descriptive statistics were calculated. Moreover, the associations between seropositivity and different factors (age, gender, preventive, etc.) were determined using logistic regression. A total of 637 participants were recruited, including 563 students, followed by 52 TAS officers, and 22 professors. The median age among was 21 years [18 - 63]. 62.0% of the participants were female, and 36.89% were male, with a male-to-female ratio = 0.59. The overall IgG and IgM seroprevalence were 92% and 6.91% respectively. We found a higher IgM seroprevalence in men than women (9.4% vs. 5.6%) and a lower IgM seroprevalence in (18-25) age group compared to (55-65) years. Low compliance with preventive measures was found with a significant IgM seroprevalence depending on non-respect of social distancing (p = 0.008). IgM seropositivity was associated with Body Mass Indice (BMI) categorized (O.R. 0.238, p = 0.043), ethnic group (O.R. 0.723, p = 0.046) and marital status (O.R. 2.399, p = 0.021). Moreover, IgG seropositivity was associated with vaccination status (O.R. 4.741, p < 0.001). Our study revealed that the majority of students and staff have already been exposed to SARS-CoV-2, which confirms the circulation of SARS-CoV-2 in PHS at the time of the survey. Our results underline the importance of seroepidemiological surveys to estimate the real impact of the COVID-19 pandemic in a community and to monitor disparities in antibody response in the population.

Keywords: COVID-19; SARS-CoV-2 antibodies; sero-epidemiological survey; Polytechnic High School; Senegal.

Introduction

91

The Coronavirus 2019 (COVID-19), newly identified in December 2019 in Wuhan, 92

China, is an infectious disease caused by Severe Acute Respiratory Syndrome 93

Coronavirus 2 (SARS-CoV-2) [1, 2]. On January 30 2020, the World Health 94

Organization (WHO) declared COVID-19 a public health emergency of global concern, 95

and on March 11, 2020, it announced the COVID-19 epidemic as a pandemic [3]. By 96

November 12, 2023, more than 697 million of people had been infected worldwide, 97

with over 6.9 million deaths [4]. 98

99 The COVID-19 outbreak had substantial economic, social, and health repercussions and damaging educational consequences [5-7]. In April 2020, the World Bank 100 estimated that higher education institutions had been closed in 175 countries and that 101 studies had been interrupted or significantly disrupted due to COVID-19, affecting 102 more than 220 million students [8]. The pandemic forced academic communities to 103 adopt online platforms for the continuity of teaching and learning activities, negatively 104 105 impacting learning outcomes, particularly in developing countries where the lack of

network infrastructures, computers, and internet access is challenging distance 106

learning in developing countries [9, 10]. 107

In Senegal, a West African country, the first case of SARS-CoV-2 was identified on 108 March 2, 2020. Since then, the number of cases has risen considerably, and the country 109 currently has more than 89,022 confirmed cases of COVID-19 and 1,971 deaths [11]. 110 The onset of the pandemic led the government authorities to close higher education 111 establishments from March 16 to August 31 2020. The reopening of the establishments 112 took place with the introduction of sanitary protocols that emphasized the 113 reinforcement of barrier measures (wearing masks, hand washing with soapy water 114 or hydroalcoholic gel, respect for social distancing and systematic taking of body 115 temperature at campus access points) [12]. However, these measures have often been 116 117

insufficient to stem the spread of the virus. Clusters quickly appeared in some

establishments, including the Cheikh Anta Diop (CAD) University, located in Dakar, 118

the capital of Senegal. 119

The failure of strategies to combat the spread of the virus could be linked to multiple 120 factors, including (i) CAD University ecosystem, with its over 80,000 students from 121 diverse origins. The consequence is overcrowding in student residences that caused 122 the spread of the virus; (ii) the university environment is mainly populated by young 123 people, who do not seem to be fully aware of the risks associated with the COVID-19 124 health crisis [13]; (iii) the promiscuity in the Halls of residence, making it difficult to 125 comply with social preventive measures; (iv) Lastly, lack of vaccine deployment and 126

reluctance was noted among young people, which also contributes to low vaccination 127

coverage in universities [14]. 128

Faced with all these difficulties, it was essential to adopt cyclical measures to manage 129

130 the COVID-19 pandemic, characterised by the virus spreading in waves [15, 16]. These

measures could involve introducing survey studies based on diagnostic testing and 131

132 mass screening protocols to diagnose and follow up with people exposed to or infected 133

with SARS-CoV-2. In practice, detecting viral RNA by RT-PCR is the reference method

for confirming the diagnosis of SARS-CoV-2 infection [17, 18]. However, access to 134

diagnostic tests still needs to be improved in poor countries [19]. The other way to 135 estimate the true extent of the epidemic is to conduct Seroprevalence surveys [20, 21]. 136 Seroepidemiological studies to detect the presence of anti-SARS-CoV-2 antibodies are 137 a valuable tool for assessing the timing of the epidemic. It can help to confirm the 138 presence of a recent infection when PCR is limited. Some antibodies, such as IgG, can 139 even be detected years after exposure [22]. Their detection can be used to identify 140 previous or recent exposure to SARS-CoV-2. By carrying out this analysis on a 141 representative population, it is possible to estimate what proportion of the population 142 has already been exposed to the new coronavirus [23]. This information is helpful in 143 identifying the epidemic phases and can help the authorities make decisions and even 144 anticipate appropriate measures to contain the pandemic's spread [24]. Sero-145 epidemiological studies have been conducted in academic institutions such as 146 universities in many countries [25-28]. However, more studies are highly relevant 147 because university communities (faculty, staff and students) could be among the most 148 exposed to SARS-CoV-2. In Senegal, no seroprevalence studies have been conducted 149 in cohorts of educational institutions.

in cohorts of educational institutions.

Therefore, we conducted an on-site screening project at Polytechnic High School (PHS),
a public institution with an inter-African vocation at CAD University from May to
August 2022 after the fourth wave of Coronavirus disease in Senegal. We aimed to

assess the true extent of previous and recent COVID-19 exposition among students

and staff and to investigate the risk factors associated with SARS-CoV-2 IgM and IgG

156 seropositivity.

2. Materials and Methods

158159

161

162

163

164

165

166

167

157

160 2.1. Study Design and Population

The SARSESP ("Etude de Seroprevalence du SARS-CoV-2 au sein de l'École Supérieure Polytechnique", in the Cheikh anta DIOP University (CAD University)) project is an on-site university population-based cross-sectional study. The sampling occurred at the PHS, an establishment of CAD University. Students, Professors, and Technicians, Administrative and Service (TAS) officers at SPS were invited by e-mail to enrol in the study. Participants were volunteers who registered online between 19 May and 18 August 2022. A questionnaire was administered to each participant after consent, blood samples were taken for SARS-CoV-2 antibody detection.

168169170

171

172

173174

175

176177

178

2.2. Sample Size Calculation

We used stratified random sampling: the first stratum concerned professors, the second TAS officers and the third students. Systematic random sampling was used within each stratum to determine the required number of subjects. Using the lists provided by the student affairs and human resources departments, we calculated the sample size based on the hypothesis of an expected seroprevalence of 45%, with a precision of 5%, a design effect of 1.96, and a nonresponse rate of 65%. We determined that >450 participants needed to be recruited. To increase the accuracy of the results, this size was multiplied by 2, giving a sample size of 898, and rounded up to 1000 to

account for any lost records. The survey step for selecting statistical units was 179 6133/1000, i.e. a step = 6. In this study, an allocation proportional to the size of each 180 stratum was used. Thus, we considered a proportion of 83.54% for students, 9.97% for 181 professors and 6.47% for TAS officers. Then, we obtained 65 TAS officers, 100 182 professors and 835 students. The inclusion criteria were age over eighteen (18) years, 183 informed consent signed, and questionnaire completion. Then, the non-inclusion 184 criteria were under 18 years of age, non-consent and contraindications to venous blood 185 sampling (anaemia, Infection or hematoma at a prospective venipuncture site, etc.). 186

187188 2.3. Questionnaire

189

190

191

192193

194

195196

197

198 199 We shared an interviewer-administered questionnaire with participants on an electronic tablet (https://enquete.ucad.sn/index.php/598685?lang=fr). The questionnaire covered points regarding different factors to assess for relationships between IgM and IgG seropositivity and these factors. Questions relating to sociodemographic characteristics were collected, such as age, sex, occupation, education level, nationality, ethnic group and accommodation type. We also collected alcohol and tobacco intake, SARS-CoV-2 vaccination status, and preventive measures related to SARS-CoV-2 practices. We provided all recruitment participants with face masks and hand sanitisers and encouraged them to practice physical and social distancing. The questionnaire on COVID-19 was posted online by the IT and Information Systems Department of CAD University.

200201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

2.4. Blood Collection and SARS-CoV-2 Antibodies Detection

After each participant signed the written consent form, a 10 mL whole blood sample was collected into a dry vacutainer tube by standard venipuncture technique. Blood samples were centrifuged at 2,500 rpm for 10 minutes. Then, the plasma was collected and stored in cryotubes at -80°C at the GRBA-BE laboratory biobank in PHS until the tests were carried out. Seropositivity to anti-SARS-CoV-2 antibodies was used as a biomarker of exposure to the SARS-CoV-2 virus. IgM class immunoglobulins were used as a marker of recent or current infection (usually from days 5-7 after symptoms appear, but sometimes later and decrease at days 15-22), and IgG class immunoglobulins were used as a biomarker of older infection (detectable from day 11 post symptom, reaching a maximum 3-4 weeks after and persist days 90 after) [29, 30]. Serological tests were performed by qualitative ELISA for IgM and quantitative ELISA for IgG following the instructions for the WANTAI SARS-CoV-2 IgM ELISA (Beijing Wantai Biological Pharmacy Enterprise, Beijing, China; Ref. WS-1196 and WS-1396) recommended by the WHO for seroepidemiological studies, which detects total antibodies (including IgM and IgG) binding the SARS-CoV-2 spike protein receptor binding domain (S1/RBD) [31]. Serum samples were analysed in duplicate according to the supplier's recommendations.

218219

220 2.5. Statistical Analyses

- 221 Statistical analyses were performed using Rstudio (version R 4.2.1) and GraphPad
- 222 Prism (version 10.1.1 (316)) softwares. Continuous variables were described as mean

223 (standard deviation) or median (interquartile range). Normally distributed variables

were compared with a t-test, and nonparametric data were compared with the Mann-

225 Whitney test. Categorical variables were presented as percent, and Fisher exact tests

or chi-squared tests were used for proportional assessments. For all statistical tests, we

227 accepted a two-sided level of significance was set at $p \le 0.05$.

228 SARS-CoV-2 seroprevalence was defined as the ratio of the number of people who

developed anti-SARS-CoV-2 antibodies to the general population. Confidence

230 intervals (95% CI) for seroprevalence were estimated using the Clopper-Pearson

method. Using logistic regressions, we sought to understand how the IgM and IgG

seropositivity are influenced by various variables such as age, gender, occupation,

education level, nationality, type of accommodation, etc. The analyses were carried

out after carefully handling the database and processing missing data.

235236

231

232

233

2.6. Ethics Statement

This research complies with ethical recommendations. The project protocol has been validated by the National Health Research Ethics Committee (CNERS) of the Ministry

of Health and Social Action. The research protocol was drawn up in accordance with

Senegalese laws and regulations governing the confidentiality of personal data. The

study was approved by the Senegalese National Ethics Committee for Research in

Health (Reference number N°000043/MSAS/CNERS/SP, 28 February 2022).

243244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

241

3. Results

3.1. Baseline characteristics of participants

From the 1000 students, professors and TAS officers of PHS who were invited to participate in the study between 19 May 2022 and 18 August 2022, 637 (63.7%) participants were finally included (Figure 1). The most represented group was students (88.38%), followed by TAS officers (8.16%), and professors (3.45%). The mean age was 23.20 years, ranging from 18 to 63 years. The population's median age was 21 years, with most participants aged 18 to 25 years, representing 85.7% of the population (Table I). 62.0% of the participants were female, and 36.89% were male, with a male-to-female ratio = 0.59. Most participants were Senegalese (94.66%) and lived in family homes (54.6%). In addition, most ethnic groups in the PHS population were Wolof (31.24%), Fula (24.33%) and Serer (21.98%). The prevalences of active smoking and taking alcohol were relatively low in the PHS community at the moment of the survey (1.9%) and (3.62%), respectively. Demographic data are shown in Table I. Calculation of body mass index also revealed the highest prevalence of normal weight (37.68%), followed by underweight (10.8%) and overweight/obesity, 8.32%). The most common blood group is O+ (47.08%). At the time of data collection, unvaccinated vs. vaccinated

261262263

264

265

266

3.2. Compliance with preventive measures and antibodies' seroprevalence

participants were 57.46% and 35.01 %) respectively.

Most respondents reported a low level of compliance with the following preventive measures recommended by the health authorities: 31.39% among participants declared that they had worn a mask always or often, and 18.21% observed a physical distance

267 (minimum 2 m) over the last 15 days. However, most participants reported a high level 268 of compliance with hand washing: 75.35% had washed their hands always or often 269 (Figure 2A). For social distancing, the majority of participants, 71.58%, reported 0-2 270 frequencies of Participation in social events during the 15 days before the survey; 70.8% 271 declared that they used public transport at least 2 times a day; and finally, 62.16% had 272 visited someone 15 days before the survey (Figure 2B).

273274

- 3.3. Seroprevalence of IgM et IgG SARS-CoV-2 antibodies
- For overall participants, 6.91% (95% CI: 4.93 8.87) were seropositive for SARS-CoV-2
- 276 IgM antibody, and 92% (95% CI: 89.90 94.11) were seropositive for SARS-CoV-2 IgG.
- 277 Then, we analysed IgM and IgG seroprevalence according to the different
- 278 characteristics of the study population shown in Table II.
- Regarding IgM seroprevalence, the results showed significant age-dependence (p < p
- 280 0.001) with higher seroprevalence in the (25-35) age group with 23.69% (95% CI: 20.39
- 281 27) compared to (18-25) age group with 5.5% (95% CI: 3.73 7.27). According to
- gender, IgM seroprevalence was higher in men, 9.4% (95% CI: 7.13 11.67) than in
- women, 5.6% (95% CI: 3.51 7.38), but no significant differences were found by sex (p
- = 0.83). There were no significant differences according to the other sociodemographic
- 285 parameters regarding IgM antibodies seropositivity, such as occupation, level of
- education, ethnic group, accommodation type and size, but with some differences
- between sub-groups. For example, depending on the type of residence, we found a
- higher IgM seroprevalence among those living in halls of residence, 7.97% (95% CI:
- 5.87 10.07) compared to those living in family homes, 6.68% (95% CI: 4.74 8.62)], p
- 290 = 0.73.
- 291 Concerning IgG seroprevalence, we found a significant difference between people
- who drank alcohol [95.24% (95% CI: 93.58 96.89)] and those who didn't [90.80%, (95% CI: 93.58 96.89)]
- 293 CI: 88.55, 93.04)], with p = 0.038. Then, a very significant difference was found
- 294 according to vaccination status, with a high seropositivity rate in vaccinated people
- 295 [96.83% (95% CI: 95.47 98.19)] compared to unvaccinated [86.58% (95% CI: 83.93 –
- 89.22)], p < 0.0001. No significant difference was found between IgG seroprevalence
- according to age groups, while IgG seroprevalence was lower in men [89.9% (95% CI:
- 298 87.60 92.24)] than in women [90.6% (95% CI: 88.33 92.87)], p = 0.98. Then, no
- significant differences were found by sex (p = 0.83). IgM and IgG seroprevalences were
- 300 higher in Professors and TAS officers than in students, yet this difference was not
- statistically significant (p = 0.71).
- 302 Concerning antibodies' seroprevalence according preventive measures, we found a
- 303 significant difference in IgM seroprevalence according to the 'number of visits made
- to someone' during the 15 days before the survey (p = 0.008) (Table III). However, we
- 305 found no significant difference in IgG seroprevalence and compliance with barrier
- 306 measures.

307

308 3.5. Risk factors associated with SARS-CoV-2 IgM and IgG seropositivity among PHS community

Multiple Logistic regression analysis didn't show an association between IgG seropositivity and the factors studied. Interestingly, an association between IgM seropositivity and participants' ethnic group [O.R. $0.723\,95\%$ CI: 0.49-0.96, (p=0.046)] was reported (Table IV). Using a univariate analysis, we found a significant association between IgM seropositivity and marital status [O.R. $2.399\,95\%$ CI: 1.08-4.87 (p=0.021)], and Body Mass Indice (BMI) categorised [O.R. $2.015\,95\%$ CI: 1.12-3.56, (p=0.016)]. In addition, on one hand, we found a significant association between vaccination and IgG seropositivity [O.R. $4.741\,95\%$ CI: 2.25-11.65, (p<0.001)]; on the other hand, no associations were observed between SARS-CoV-2 seropositivity and sex and age groups. Finally, no significant association were found between IgM and IgG seropositivity and preventive measures (Table V).

321 322

310

311

312

313

314

315

316

317

318

319

320

323324

325

326327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348349

350 351

352

353

4. Discussion This is the first sero-epidemiological survey of COVID-19 carried out in an educational establishment in Senegal. The study aimed to determine the seroprevalence of IgM and IgG SARS-CoV-2 antibodies and associated risk factors in order to assess the extent of virus exposure within the Polytechnic High School in Cheikh Anta Diop University. The survey was carried out on samples collected from personnel and students from May 2022 to August 2022, after the fourth wave of COVID-19 in Senegal. A total of 637 participants were included in the study, 62% of whom were women and 37% men. The median age was 21, which is justified by the fact that the study was conducted in a university environment. Consequently, the study population predominantly comprises students representing around 86% of the participants. We showed high IgG and IgM SARS-CoV-2 antibody seroprevalences of 92% (95% CI: 89.90 – 94.11) and 6.91% (95% CI: 4.93 – 8.87), respectively. The IgM seroprevalence indicates that the virus was circulating within PHS at the time of the survey, with people who were currently or recently infected. Indeed, in seroprevalence surveys, it is recommended to use IgM and IgG detection to diagnose recent and previous infections [32]. IgM antibody levels rise around a week after the initial infection, indicating a recent infection [22]. IgG antibodies appear later than IgM antibodies (generally within 14 days of infection). They can persist for up to a year [33, 34], meaning that IgG antibodies serve as an indicator of an old infection [35]. The very IgG high seroprevalence could be due to increased exposure to the SARS-CoV-2 virus and the anti-COVID vaccination policy implemented by the authorities. Data from the Ministry of Health showed that our study occurred after the fourth wave of COVID-19 in Senegal in January 2022, and the deployment of the COVID-19 vaccine began in February 2021 [36], which could explain our result. The first seroprevalence surveys carried out in Senegal were conducted in 2020 after the first wave and showed a lower seroprevalence of around 20%. Between June and September 2020, Seck et al. found a SARS-CoV-2 seroprevalence rate of 21.1% (95% CI = 16.7–26.1%) [37]. During the same period, Ahouidi et al. conducted a study between June and October 2020. They found that the overall positivity rate was 20.4% and significant geographical differences in seropositivity with a higher seroprevalence in Dakar, around 40% [38]. Then, Talla *et al.* found an adjusted national prevalence of anti-SARS-CoV-2 IgG/IgM in Senegal estimated to be 28.4% between October 24 and November 26, 2020 [39]. A high SARS-CoV-2 seroprevalences and its variability between localities were also reported in the second national population based cross-sectional survey (72,2%) conducted in November 2021 [40] and among pregnant women attending the antenatal consultation (69,4%) during the second and third waves of COVID-19 in Senegal [41] .

Results showed a sharp increase in seroprevalence since 2020 in Senegal, and data corroborating the finding that several variants have circulated in the country, including the delta variant, which has been the most deadly and caused a peak in the number of confirmed cases in July 2021 [42]. Study carried out in Africa at the same time as our survey showed similarly high seroprevalence, with 74% between July and August 2022 in Bangui, Central African Republic [43]. In Nigeria, in early 2021, there was a high SARS-CoV-2 seroprevalence of 72.4% [44]. Given this situation, it seems very important to carry out cyclical epidemiological survey studies to measure the extent of the spread of the SARS-CoV-2.

Interestingly, we found a higher IgM seroprevalence in men than women (9.4% vs. 5.6%). Then, our result would suggest that men are more sensitive to infection and/or reinfection with SARS-CoV-2 than women. A study conducted at the start of the pandemic by Takahashi *et al.* showed that men were more susceptible to severe forms of COVID-19 than women [45]. Gender differences in immune responses were also reported, with higher levels of pro-inflammatory cytokines (IL-8 and IL-18) and a more robust induction of non-classical monocytes in men [46]. This is consistent with studies that analysed the sex difference in antibody responses [47]. In further studies, it will be interesting compare immune responses according to gender and serological status in order to discover the mechanisms underlying sex differences.

Our results also showed a different distribution by age group, with lower IgM seroprevalence in younger individuals, particularly those aged 18-25 years, compared to those aged 55-65 years (5.5% and 33.34%, respectively) with a p < 0.001. The 18-25 age group appears less affected by recent infections. This reinforces the data showing that young people are less affected by SARS-CoV-2 infection [48]. Furthermore, they often experience an asymptomatic or mild SARS-CoV-2 infection associated with lower serum titers [49]. In Senegal, during the first wave, it was reported that seroprevalence of SARS-CoV-2 was higher in patients older than 65 years [37].

We investigated whether there was a link between the type of residence and IgM seroprevalence to determine the proportion of new infections accordingly. Surprisingly, we didn't find a significant difference in terms of IgM seroprevalence among those living in halls of residence [7.97% (95% CI: 5.87 - 10.07)] compared to those living in family homes [6.68% (95% CI: 4.74 - 8.62)], p = 0.73. This invalidates our hypothesis that the particular ecosystem of CAD University, with its over 80,000 students from diverse origins, would constitute a niche for spreading the virus, which is not proven in our study. It also appears that, even though the PHS community is mainly be composed by young people, they do not seem to facilitate new infection, contrary to what has been reported in other studies [48, 50].

Concerning compliance with preventive measures, we found a low level of compliance 398 with preventive measures recommended by the health authorities, particularly for 399 wearing masks (31.40%) and keeping a physical distance (minimum 2 m) (17.42%). 400 However, most participants reported high-level compliance with hand washing 401 (75.35%). Social distancing and staying at home were also registered although to a 402 lower degree. Our results were in contradiction with those of Kearney et al. who 403 observed high compliance with recommended COVID-19 prevention behaviors 404 among their sample of Senegal respondents, particularly for masking and personal 405 hygiene practices [51]. This difference could be explained by the fact that our study 406 population is younger and less inclined to comply with preventive measures [52, 53]. 407 Our findings revealed that IgM seropositivity depends on the 'number of visits made 408 to someone', meaning non-respect of social distancing (p = 0.008), which shows the 409 importance of WHO measures concerning the adoption of extensive social distancing 410 as a non-pharmaceutical intervention to reduce the infection's spread and the 411 412 associated mortalities [54]. However, studies have shown that the impact of social distancing measures depends upon a host of demographic, environmental, and 413 economic dimensions [55]. 414

Regarding vaccination, around 35% of participants had been partially or totally vaccinated, which is higher than the national vaccination rate of 16.9% at the moment of the survey [56]. This could be explained by our population's education level and knowledge of vaccination's stakes. Efforts were also made by the CAD University authorities, who set up a vaccination campaign at various sites during October 2021. However, the vaccination rate remains low compared to the national level, where more than 70% of the population vaccinated since the pandemic started [57].

Furthermore, we found no significant differences in IgM seroprevalences between vaccinated and unvaccinated individuals. It would, therefore, appear that vaccination does not protect against the new variants and reinfections, as has already been demonstrated in numerous studies [58-60] indeed, WHO recommendations suggest that seasonal vaccination is necessary to protect against new variants [61].

427

428

429

430

431

432

433

434

We investigated the association of sociodemographic, clinical and lifestyle factors, such as BMI, blood type, smoking and alcohol consumption, with seropositivity using logistics. Then, we found an association between BMI categorised and IgM seropositivity (O.R. 0.238, p = 0.043). Previous studies have shown that obese individuals (BMI > 30 kg/m²) were significantly more likely to be seropositive. It is uncertain whether the raised seroprevalence in these groups represents a greater risk of SARS-CoV-2 infection. However, obese individuals are known to experience more severe COVID-19 symptoms [62, 63].

Interestingly, a significant association between IgM seropositivity and ethnic group was found (O.R. 0.723, p = 0.046), suggesting a difference in susceptibility to SARS-CoV2- depending on race and ethnicity. According to previous findings, it seems there are disparities in the effects of COVID-19 infection among different racial/ethnic groups [64, 65]. Then, understanding the mechanisms for the disparity will help to evaluate the risk for COVID-19 according to ethnicity.

Our findings showed that IgM seropositivity was associated with marital status (unmarried/married) (O.R. 2.39, p = 0.021); another study reveals that transmission of SARS-CoV-2 is variable among different people within the home. For instance, the risk for infection was higher between spouses, at 43%, which could be a reflection of transmission through intimacy or longer or more direct exposure [66].

Regarding vaccination status, we found a relationship between vaccination and IgG seroprevalence (O.R. 4.741, p < 0.001), showing that people who had received vaccine doses were four times more likely to produce anti-SARS-CoV-2 antibodies than those who had not. It will be interesting to determine the IgG-neutralizing antibodies and to determine antibody levels according to vaccination status and type. Indeed, it has been shown that vaccines from different manufacturers might induce different antibody responses [67].

Some limitations of our study must be considered. By design, we carried out an onsite university population-based cross-sectional study. Thus, the results cannot be extrapolated directly to the general CAD University population. Participants were subjected to recall bias when completing the questionnaires, particularly preventive measures at the time of contact. We also noted a very low level of participation from professors and TAS officers. This constitutes a bias in the statistical calculations. Missing data for certain criteria and non-prefer responders were a limitation for statistics. To date, our study is the only SARS-CoV-2 sero-epidemiological survey conducted in a university community in Senegal. Data on the Serological testing performed by measuring IgM and IgG immunoglobulins against the SARS-CoV-2 targeting peak S1 protein separately is a strength of our study. This allowed us to differentiate recent from previous infection. Finally, with our questionnaire we were able to collect a lot of data, which was useful in calculating associations with risk factors.

In summary, our analysis of more than 630 subjects from Polytechnic High School community members estimated the extent of exposure to SARS-CoV-2. Our study revealed a high seroprevalence from May-August 2022 following the fourth wave of COVID-19 in Senegal. Our results show that the majority of students and staff have already been exposed to SARS-CoV-2 and confirm the circulation of the virus (SARS-CoV-2) at the time of the survey as shown by the high IgM and IgG seroprevalence. The data show a link between seropositivity and various factors such as age, noncompliance with prevention measures. These results underline the importance of seroepidemiological surveys to estimate the real impact of the COVID-19 pandemic and the disparities between populations in order to establish a profile of the transmission dynamics of the virus. In addition, these results may be essential for the CAD university in the event of the emergence of future waves in order to make appropriate decisions and put in place means of monitoring the evolution of the pandemic after the relaxation of social distancing measures and the implementation of a vaccination schedule at CAD University, which will serve as a basis for other universities in Senegal.

- 485 Author Contributions: "Conceptualization, F.T. and A.A.M.D, C.M.N, M.D.;
- methodology, F.T., A.A.M.D., C.S.C.A.N., S.S., S.D.T, S.C., A.S., D.D., and M.N.M;
- 487 software, F.T., C.S.C.A.N., I.D., D.D., K.K., I.D.; A.L.D, M.D..; validation, F.T.,
- 488 A.A.M.D., C.M.N., S.M.S.; formal analysis, F.T., K.K, C.S.C.A.N., I.D., D.D.; A.L.D.,
- 489 M.D.; investigation, sample collection and biobank management, F.T., A.A.M.D.,
- 490 M.N.M, C.S.C.A.N, D.D., S.C., S.S., S.D.T., A.S.; resources, F.T., A.A.M.D., S.M.S, M.D.;
- data curation, F.T., S.S., C.S.C.A.N., D.D.; writing—original draft prepa-ration, F.T.;
- 492 writing—review and editing, F.T., A.A.M.D., MNM, MD, CMN, KK, ID, SMS;
- visualization, F.T, A.A.M.D.; supervision, F.T., A.A.M.D., S.M.S., M.D., C.M.N; project
- administration, F.T.; funding acquisition, F.T., A.A.M.D., and C.M.N. All authors have
- read and agreed to the published version of the manuscript

496

Funding: This research was funded by Polytechnique High School competitive research impulse fund.

499

- 500 **Institutional Review Board Statement:** The study was conducted in accordance with
- 501 the Decla-ration of Helsinki, and approved approved by the Senegalese National
- 502 Ethics Committee for Research in Health (Reference number
- 503 N°000043/MSAS/CNERS/SP, 28 February 2022).

504

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

507508

Data Availability Statement: Not applicable.

509

- 510 **Acknowledgments:** The authors would like to thank the top management of the
- "Ecole Supéri-eure Polytechnique de Dakar" for financial support and all students,
- 512 Technicians, Administrative, Service officer and professors' members who voluntarily
- 513 participated to the study.

514

Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results".

518519

References

- 1. Asselah T, Durantel D, Pasmant E, Lau G, Schinazi RF. COVID-19: Discovery, diagnostics and drug development. J Hepatol. 2021;74(1):168-84. Epub 20201008. doi: 10.1016/j.jhep.2020.09.031.
- PubMed PMID: 33038433; PubMed Central PMCID: PMCPMC7543767.
- 523 2. Yesudhas D, Srivastava A, Gromiha MM. COVID-19 outbreak: history, mechanism,
- transmission, structural studies and therapeutics. Infection. 2021;49(2):199-213. Epub 20200904. doi:
- 525 10.1007/s15010-020-01516-2. PubMed PMID: 32886331; PubMed Central PMCID: PMCPMC7472674.
- 526 3. WHO Director-General's opening remarks at the media briefing on COVID19 -March 2020.
- 527 4. https://www.worldometers.info/coronavirus/ (accessed November 12, 2023).
- 528 5. Mofijur M, Fattah IMR, Alam MA, Islam A, Ong HC, Rahman SMA, et al. Impact of COVID-19
- on the social, economic, environmental and energy domains: Lessons learnt from a global pandemic.

- 530 Sustain Prod Consum. 2021;26:343-59. Epub 20201014. doi: 10.1016/j.spc.2020.10.016. PubMed PMID:
- 531 33072833; PubMed Central PMCID: PMCPMC7556229.
- 532 6. Hosseinzadeh P, Zareipour M, Baljani E, Moradali MR. Social Consequences of the COVID-19
- Pandemic. A Systematic Review. Invest Educ Enferm. 2022;40(1). doi: 10.17533/udea.iee.v40n1e10.
- PubMed PMID: 35485623; PubMed Central PMCID: PMCPMC9052715.
- 535 7. Shang Y, Li H, Zhang R. Effects of Pandemic Outbreak on Economies: Evidence From Business
- 536 History Context. Front Public Health. 2021;9:632043. Epub 20210312. doi: 10.3389/fpubh.2021.632043.
- PubMed PMID: 33777885; PubMed Central PMCID: PMCPMC7994505.
- 538 8. World Bank Open Data. Data. https://data.worldbank.org/ (2021).
- 9. Mok KH. Impact of COVID-19 on Higher Education: Critical Reflections. High Educ Policy.
- 540 2022;35(3):563-7. Epub 20220811. doi: 10.1057/s41307-022-00285-x. PubMed PMID: 35971428; PubMed
- 541 Central PMCID: PMCPMC9365678.
- 542 10. Selvaraj A, Radhin V, Ka N, Benson N, Mathew AJ. Effect of pandemic based online education
- on teaching and learning system. Int J Educ Dev. 2021;85:102444. Epub 20210608. doi:
- 544 10.1016/j.ijedudev.2021.102444. PubMed PMID: 34518732; PubMed Central PMCID: PMCPMC8426326.
- 545 11. https://www.worldometers.info/coronavirus/country/senegal/ (accessed
- 546 November 12, 2023).
- 547 12. Diallo AI, Faye A, Tine JAD, Ba MF, Gaye I, Bonnet E, et al. Factors associated with the
- 548 acceptability of government measures to address COVID-19 in Senegal. Rev Epidemiol Sante Publique.
- 549 2022;70(3):109-16. Epub 20220331. doi: 10.1016/j.respe.2022.03.123. PubMed PMID: 35491335; PubMed
- 550 Central PMCID: PMCPMC8968153.
- 551 13. Ba MF, Ridde V, Diallo AI, Tine JAD, Kane B, Gaye I, et al. Acceptability of contact management
- and care of simple cases of COVID-19 at home: a cross-sectional study in Senegal. Trans R Soc Trop Med
- 553 Hyg. 2022;116(12):1214-22. doi: 10.1093/trstmh/trac094. PubMed PMID: 36222221; PubMed Central
- 554 PMCID: PMCPMC9619604.
- 555 14. Nguyen KH, Nguyen K, Mansfield K, Allen JD, Corlin L. Child and adolescent COVID-19
- vaccination status and reasons for non-vaccination by parental vaccination status. Public Health.
- 557 2022;209:82-9. Epub 20220613. doi: 10.1016/j.puhe.2022.06.002. PubMed PMID: 35870290; PubMed
- 558 Central PMCID: PMCPMC9189141.
- 559 15. Zhou Y, Rahman MM, Khanam R. The impact of the government response on pandemic control
- in the long run-A dynamic empirical analysis based on COVID-19. PLoS One. 2022;17(5):e0267232. Epub
- 561 20220504. doi: 10.1371/journal.pone.0267232. PubMed PMID: 35507588; PubMed Central PMCID:
- 562 PMCPMC9067654.
- 563 16. Bedford J, Enria D, Giesecke J, Heymann DL, Ihekweazu C, Kobinger G, et al. Living with the
- 564 COVID-19 pandemic: act now with the tools we have. Lancet. 2020;396(10259):1314-6. Epub 20201008.
- 565 doi: 10.1016/S0140-6736(20)32117-6. PubMed PMID: 33038947; PubMed Central PMCID:
- 566 PMCPMC7544497.
- 567 17. Torretta S, Zuccotti G, Cristofaro V, Ettori J, Solimeno L, Battilocchi L, et al. Diagnosis of SARS-
- 568 CoV-2 by RT-PCR Using Different Sample Sources: Review of the Literature. Ear Nose Throat J.
- 569 2021;100(2_suppl):131S-8S. Epub 20200831. doi: 10.1177/0145561320953231. PubMed PMID: 32865458;
- 570 PubMed Central PMCID: PMCPMC7459180.
- 571 18. Chung YS, Lee NJ, Woo SH, Kim JM, Kim HM, Jo HJ, et al. Validation of real-time RT-PCR for
- 572 detection of SARS-CoV-2 in the early stages of the COVID-19 outbreak in the Republic of Korea. Sci
- 573 Rep. 2021;11(1):14817. Epub 20210720. doi: 10.1038/s41598-021-94196-3. PubMed PMID: 34285290;
- 574 PubMed Central PMCID: PMCPMC8292370.
- 575 19. Maniruzzaman M, Islam MM, Ali MH, Mukerjee N, Maitra S, Kamal MA, et al. COVID-19
- 576 diagnostic methods in developing countries. Environ Sci Pollut Res Int. 2022;29(34):51384-97. Epub
- 577 20220527. doi: 10.1007/s11356-022-21041-z. PubMed PMID: 35619009; PubMed Central PMCID:
- 578 PMCPMC9135468.
- 579 20. Lai CC, Wang JH, Hsueh PR. Population-based seroprevalence surveys of anti-SARS-CoV-2
- 580 antibody: An up-to-date review. Int J Infect Dis. 2020;101:314-22. Epub 20201009. doi:
- 581 10.1016/j.ijid.2020.10.011. PubMed PMID: 33045429; PubMed Central PMCID: PMCPMC7546669.

- 582 21. Rostami A, Sepidarkish M, Leeflang MMG, Riahi SM, Nourollahpour Shiadeh M, Esfandyari S,
- 583 et al. SARS-CoV-2 seroprevalence worldwide: a systematic review and meta-analysis. Clin Microbiol
- 584 Infect. 2021;27(3):331-40. Epub 20201024. doi: 10.1016/j.cmi.2020.10.020. PubMed PMID: 33228974;
- PubMed Central PMCID: PMCPMC7584920.
- Hou H, Wang T, Zhang B, Luo Y, Mao L, Wang F, et al. Detection of IgM and IgG antibodies in
- patients with coronavirus disease 2019. Clin Transl Immunology. 2020;9(5):e01136. Epub 20200506. doi:
- 588 10.1002/cti2.1136. PubMed PMID: 32382418; PubMed Central PMCID: PMCPMC7202656.
- 589 23. Feikin DR, Widdowson MA, Mulholland K. Estimating the Percentage of a Population Infected
- 590 with SARS-CoV-2 Using the Number of Reported Deaths: A Policy Planning Tool. Pathogens. 2020;9(10).
- 591 Epub 20201013. doi: 10.3390/pathogens9100838. PubMed PMID: 33066231; PubMed Central PMCID:
- 592 PMCPMC7602107.
- 593 24. Cascini F, Failla G, Gobbi C, Pallini E, Hui J, Luxi W, et al. A cross-country comparison of Covid-
- 19 containment measures and their effects on the epidemic curves. BMC Public Health. 2022;22(1):1765.
- 595 Epub 20220917. doi: 10.1186/s12889-022-14088-7. PubMed PMID: 36115936; PubMed Central PMCID:
- 596 PMCPMC9482299.
- 597 25. Vusirikala A, Whitaker H, Jones S, Tessier E, Borrow R, Linley E, et al. Seroprevalence of SARS-
- 598 CoV-2 antibodies in university students: Cross-sectional study, December 2020, England. J Infect.
- 599 2021;83(1):104-11. Epub 20210429. doi: 10.1016/j.jinf.2021.04.028. PubMed PMID: 33933527; PubMed
- 600 Central PMCID: PMCPMC8081745.
- 601 26. Tsitsilonis OE, Paraskevis D, Lianidou E, Pierros V, Akalestos A, Kastritis E, et al.
- 602 Seroprevalence of Antibodies against SARS-CoV-2 among the Personnel and Students of the National
- and Kapodistrian University of Athens, Greece: A Preliminary Report. Life (Basel). 2020;10(9). Epub
- 604 20200921. doi: 10.3390/life10090214. PubMed PMID: 32967110; PubMed Central PMCID:
- 605 PMCPMC7555935.
- 606 27. Arnold CRK, Srinivasan S, Rodriguez S, Rydzak N, Herzog CM, Gontu A, et al. SARS-CoV-2
- 607 Seroprevalence in a University Community: A Longitudinal Study of the Impact of Student Return to
- 608 Campus on Infection Risk Among Community Members. medRxiv. 2021. Epub 20210917. doi:
- 609 10.1101/2021.02.17.21251942. PubMed PMID: 33619497; PubMed Central PMCID: PMCPMC7899462.
- 610 28. Migliara G, Renzi E, Baccolini V, Cerri A, Donia P, Massimi A, et al. Predictors of SARS-CoV-2
- 611 Infection in University Students: A Case-Control Study. Int J Environ Res Public Health. 2022;19(21).
- 612 Epub 20221103. doi: 10.3390/ijerph192114376. PubMed PMID: 36361257; PubMed Central PMCID:
- 613 PMCPMC9655450.
- 614 29. Denning DW, Kilcoyne A, Ucer C. Non-infectious status indicated by detectable IgG antibody
- 615 to SARS-CoV-2. Br Dent J. 2020;229(8):521-4. Epub 20201023. doi: 10.1038/s41415-020-2228-9. PubMed
- 616 PMID: 33097885; PubMed Central PMCID: PMCPMC7582419.
- 617 30. Assaid N, Arich S, Charoute H, Akarid K, Anouar Sadat M, Maaroufi A, et al. Kinetics of SARS-
- 618 CoV-2 IgM and IgG Antibodies 3 Months after COVID-19 Onset in Moroccan Patients. Am J Trop Med
- 619 Hyg. 2023;108(1):145-54. Epub 20221212. doi: 10.4269/ajtmh.22-0448. PubMed PMID: 36509045; PubMed
- 620 Central PMCID: PMCPMC9833093.
- 621 31. GeurtsvanKessel CH, Okba NMA, Igloi Z, Bogers S, Embregts CWE, Laksono BM, et al. An
- 622 evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment. Nat
- 623 Commun. 2020;11(1):3436. Epub 20200706. doi: 10.1038/s41467-020-17317-y. PubMed PMID: 32632160;
- 624 PubMed Central PMCID: PMCPMC7338506.
- 625 32. Wajnberg A, Mansour M, Leven E, Bouvier NM, Patel G, Firpo-Betancourt A, et al. Humoral
- response and PCR positivity in patients with COVID-19 in the New York City region, USA: an
- 627 observational study. Lancet Microbe. 2020;1(7):e283-e9. Epub 20200925. doi: 10.1016/S2666-
- 628 5247(20)30120-8. PubMed PMID: 33015652; PubMed Central PMCID: PMCPMC7518831.
- 629 33. Ahmad A, Haq M, Rehman A, Haq NU. Anti-nucleocapsid IgG antibodies in SARS-CoV-2
- 630 recovered health care workers: One year follow-up study. Int J Immunopathol Pharmacol.
- $631 \qquad 2023; 37:3946320231187744. \ doi: 10.1177/03946320231187744. \ PubMed\ PMID: 37394899; PubMed\ Central$
- 632 PMCID: PMCPMC10328170.
- 633 34. Haveri A, Ekstrom N, Solastie A, Virta C, Osterlund P, Isosaari E, et al. Persistence of
- 634 neutralizing antibodies a year after SARS-CoV-2 infection in humans. Eur J Immunol. 2021;51(12):3202-

- 635 13. Epub 20211008. doi: 10.1002/eji.202149535. PubMed PMID: 34580856; PubMed Central PMCID:
- 636 PMCPMC8646652.
- 637 35. Sun B, Feng Y, Mo X, Zheng P, Wang Q, Li P, et al. Kinetics of SARS-CoV-2 specific IgM and
- 638 IgG responses in COVID-19 patients. Emerg Microbes Infect. 2020;9(1):940-8. doi:
- 639 10.1080/22221751.2020.1762515. PubMed PMID: 32357808; PubMed Central PMCID: PMCPMC7273175.
- 640 36. SMHSA (Senegalese Ministry of Health and Social Action)2022 [Final report of the 2nd seroprevalence survey of Covid-19 in Senegal, 2022.
- 642 37. Seck SM, Mbow M, Kane Y, Cisse MM, Faye G, Kama A, et al. Prevalence of SARS-CoV-2
- antibodies in hemodialysis patients in Senegal: a multicenter cross-sectional study. BMC Nephrol.
- 644 2021;22(1):384. Epub 20211117. doi: 10.1186/s12882-021-02582-w. PubMed PMID: 34789170; PubMed
- 645 Central PMCID: PMCPMC8595275.
- 646 38. Ahouidi AD, Anderson M, Diedhiou CK, Dia A, Mbow M, Dia Y, et al. Seroprevalence of SARS-
- 647 CoV-2 IgG antibodies in a healthcare setting during the first pandemic wave in Senegal. IJID Reg.
- 648 2022;2:96-8. Epub 20211224. doi: 10.1016/j.ijregi.2021.12.008. PubMed PMID: 35721431; PubMed Central
- 649 PMCID: PMCPMC8702669.
- 650 39. Talla C, Loucoubar C, Roka JL, Barry MA, Ndiaye S, Diarra M, et al. Seroprevalence of anti-
- 651 SARS-CoV-2 antibodies in Senegal: a national population-based cross-sectional survey, between
- October and November 2020. IJID Reg. 2022;3:117-25. Epub 20220305. doi: 10.1016/j.ijregi.2022.02.007.
- PubMed PMID: 35720135; PubMed Central PMCID: PMCPMC8897837.
- 654 40. SMHSA (Senegalese Ministry of Health and Social Action)2023 [Final report of the 2nd seroprevalence survey of Covid-19 in Senegal, 2023.
- 656 41. Diouara, A. A., et al. High Exposure to SARS-CoV-2 among Pregnant Women after the First 657 and Second Waves of COVID-19 in Senegal. Preprints. doi: 10.20944/preprints202310.1684.v1
- 658 42. Ndiaye AJS, Beye M, Lo G, Kacel I, Sow A, Leye N, et al. Genomic Epidemiology of SARS-CoV-2
- 659 in Urban Settings in Senegal. Viruses. 2023;15(6). Epub 20230524. doi: 10.3390/v15061233. PubMed
- 660 PMID: 37376533; PubMed Central PMCID: PMCPMC10302768.
- 661 43. Manirakiza A, Malaka C, Longo JD, Yambiyo BM, Diemer SH, Namsenei J, et al. Sero-
- 662 prevalence of anti-SARS-CoV-2 antibodies among communities between July and August 2022 in
- 663 Bangui, Central African Republic. J Public Health Afr. 2023;14(8):2315. Epub 20230605. doi:
- 664 10.4081/jphia.2023.2315. PubMed PMID: 37753434; PubMed Central PMCID: PMCPMC10519115.
- 665 44. Akanmu S, Herrera BB, Chaplin B, Ogunsola S, Osibogun A, Onawoga F, et al. High SARS-CoV-
- 2 seroprevalence in Lagos, Nigeria with robust antibody and cellular immune responses. J Clin Virol
- 667 Plus. 2023;3(3):100156. Epub 20230624. doi: 10.1016/j.jcvp.2023.100156. PubMed PMID: 37388808;
- 668 PubMed Central PMCID: PMCPMC10289822.
- 669 45. Takahashi T, Wong P, Ellingson MK, Lucas C, Klein J, Israelow B, et al. Sex differences in
- immune responses to SARS-CoV-2 that underlie disease outcomes. medRxiv. 2020. Epub 20200626. doi:
- 671 10.1101/2020.06.06.20123414. PubMed PMID: 32577695; PubMed Central PMCID: PMCPMC7302304.
- 672 46. Zhang H, Tang Y, Tao J. Sex-Related Overactivation of NLRP3 Inflammasome Increases
- 673 Lethality of the Male COVID-19 Patients. Front Mol Biosci. 2021;8:671363. Epub 20210604. doi:
- 674 10.3389/fmolb.2021.671363. PubMed PMID: 34150848; PubMed Central PMCID: PMCPMC8212049.
- 675 47. Zeng F, Dai C, Cai P, Wang J, Xu L, Li J, et al. A comparison study of SARS-CoV-2 IgG antibody
- between male and female COVID-19 patients: A possible reason underlying different outcome between
- 677 sex. J Med Virol. 2020;92(10):2050-4. Epub 20200522. doi: 10.1002/jmv.25989. PubMed PMID: 32383183;
- 678 PubMed Central PMCID: PMCPMC7267228.
- 679 48. Felsenstein S, Hedrich CM. SARS-CoV-2 infections in children and young people. Clin Immunol.
- 680 2020;220:108588. Epub 20200906. doi: 10.1016/j.clim.2020.108588. PubMed PMID: 32905851; PubMed
- 681 Central PMCID: PMCPMC7474910.
- 682 49. Backhaus I, Hermsen D, Timm J, Boege F, Lubke N, Degode T, et al. SARS-CoV-2 seroprevalence
- and determinants of infection in young adults: a population-based seroepidemiological study. Public
- 684 Health. 2022;207:54-61. Epub 20220323. doi: 10.1016/j.puhe.2022.03.009. PubMed PMID: 35490440;
- 685 PubMed Central PMCID: PMCPMC8940565.

- 686 50. Lu X, Zhang L, Du H, Zhang J, Li YY, Qu J, et al. SARS-CoV-2 Infection in Children. N Engl J
- 687 Med. 2020;382(17):1663-5. Epub 20200318. doi: 10.1056/NEJMc2005073. PubMed PMID: 32187458;
- 688 PubMed Central PMCID: PMCPMC7121177.
- 689 51. Kearney M, Bornstein M, Fall M, Nianogo R, Glik D, Massey P. Cross-sectional study of COVID-
- 690 19 knowledge, beliefs and prevention behaviours among adults in Senegal. BMJ Open.
- 691 2022;12(5):e057914. Epub 20220526. doi: 10.1136/bmjopen-2021-057914. PubMed PMID: 35618332;
- 692 PubMed Central PMCID: PMCPMC9136694.
- 693 52. Jaureguizar J, Redondo I, Galende N, Ozamiz N. Factors related to compliance with the COVID-
- 19 health regulations among young people. World J Psychiatry. 2021;11(12):1247-58. Epub 20211219.
- doi: 10.5498/wjp.v11.i12.1247. PubMed PMID: 35070774; PubMed Central PMCID: PMCPMC8717041.
- 696 53. Kim JK, Crimmins EM. How does age affect personal and social reactions to COVID-19: Results
- from the national Understanding America Study. PLoS One. 2020;15(11):e0241950. Epub 20201110. doi:
- 698 10.1371/journal.pone.0241950. PubMed PMID: 33170903; PubMed Central PMCID: PMCPMC7654776.
- 699 54. Yoo TK, Oh E, Kim HK, Ryu IH, Lee IS, Kim JS, et al. Deep learning-based smart speaker to
- 700 confirm surgical sites for cataract surgeries: A pilot study. PLoS One. 2020;15(4):e0231322. Epub
- 701 20200409. doi: 10.1371/journal.pone.0231322. PubMed PMID: 32271836; PubMed Central PMCID:
- 702 PMCPMC7144990.
- 703 55. Prakash N, Srivastava B, Singh S, Sharma S, Jain S. Effectiveness of social distancing
- 704 interventions in containing COVID-19 incidence: International evidence using Kalman filter. Econ Hum
- 705 Biol. 2022;44:101091. Epub 20211202. doi: 10.1016/j.ehb.2021.101091. PubMed PMID: 34894622; PubMed
- 706 Central PMCID: PMCPMC8638209.
- 56. Singhal S, Prakash N. A narrative inquiry into the meaning of career identity of Indian emerging
- 708 adults amid Covid-19. Int J Educ Vocat Guid. 2023:1-26. Epub 20230316. doi: 10.1007/s10775-023-09590-2.
- 709 PubMed PMID: 37360271; PubMed Central PMCID: PMCPMC10019401.
- 710 57. Garg T, Votta CM, Prakash N, Deldin PJ. An investigation into the effectiveness of Mood Lifters
- in the context of trauma exposure. Psychol Serv. 2023. Epub 20230824. doi: 10.1037/ser0000789. PubMed
- 712 PMID: 37616078.
- 713 58. Van Egeren D, Stoddard M, White LF, Hochberg NS, Rogers MS, Zetter B, et al. Vaccines Alone
- 714 Cannot Slow the Evolution of SARS-CoV-2. Vaccines (Basel). 2023;11(4). Epub 20230416. doi:
- 715 10.3390/vaccines11040853. PubMed PMID: 37112765; PubMed Central PMCID: PMCPMC10143044.
- 716 59. Malik JA, Ahmed S, Mir A, Shinde M, Bender O, Alshammari F, et al. The SARS-CoV-2
- 717 mutations versus vaccine effectiveness: New opportunities to new challenges. J Infect Public Health.
- 718 2022;15(2):228-40. Epub 20220105. doi: 10.1016/j.jiph.2021.12.014. PubMed PMID: 35042059; PubMed
- 719 Central PMCID: PMCPMC8730674.
- 720 60. Lopez Bernal J, Gower C, Andrews N, Public Health England Delta Variant Vaccine
- 721 Effectiveness Study G. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. Reply.
- 722 N Engl J Med. 2021;385(25):e92. Epub 20211110. doi: 10.1056/NEJMc2113090. PubMed PMID: 34758250.
- 723 61. Cohen JI, Burbelo PD. Reinfection With SARS-CoV-2: Implications for Vaccines. Clin Infect Dis.
- 724 2021;73(11):e4223-e8. doi: 10.1093/cid/ciaa1866. PubMed PMID: 33338197; PubMed Central PMCID:
- 725 PMCPMC7799323.
- 726 62. Wolff D, Nee S, Hickey NS, Marschollek M. Risk factors for Covid-19 severity and fatality: a
- 727 structured literature review. Infection. 2021;49(1):15-28. Epub 20200828. doi: 10.1007/s15010-020-01509-
- 728 1. PubMed PMID: 32860214; PubMed Central PMCID: PMCPMC7453858.
- 729 63. Aburto S, Cisterna M, Acuna J, Ruiz C, Viscardi S, Marquez JL, et al. Obesity as a Risk Factor
- 730 for Severe COVID-19 in Hospitalized Patients: Epidemiology and Potential Mechanisms. Healthcare
- 731 (Basel). 2022;10(10). Epub 20220922. doi: 10.3390/healthcare10101838. PubMed PMID: 36292285;
- 732 PubMed Central PMCID: PMCPMC9601462.
- 733 64. Mackey K, Ayers CK, Kondo KK, Saha S, Advani SM, Young S, et al. Racial and Ethnic
- 734 Disparities in COVID-19-Related Infections, Hospitalizations, and Deaths: A Systematic Review. Ann
- 735 Intern Med. 2021;174(3):362-73. Epub 20201201. doi: 10.7326/M20-6306. PubMed PMID: 33253040;
- 736 PubMed Central PMCID: PMCPMC7772883.

- 737 65. Carethers JM. Insights into disparities observed with COVID-19. J Intern Med. 2021;289(4):463-
- 73. Epub 20201206. doi: 10.1111/joim.13199. PubMed PMID: 33164230; PubMed Central PMCID:
- 739 PMCPMC9325576.

748

- 740 66. Fogh K, Eriksen ARR, Hasselbalch RB, Kristensen ES, Bundgaard H, Nielsen SD, et al.
- 741 Seroprevalence of SARS-CoV-2 antibodies in social housing areas in Denmark. BMC Infect Dis.
- 742 2022;22(1):143. Epub 20220210. doi: 10.1186/s12879-022-07102-1. PubMed PMID: 35144550; PubMed
- 743 Central PMCID: PMCPMC8830972.
- 744 67. Megasari NLA, Yamani LN, Juniastuti J, Lusida MI, Mori Y. Seroprevalence of SARS-CoV-2
- 745 anti-spike IgG antibody among COVID-19 vaccinated individuals residing in Surabaya, East Java,
- 746 Indonesia. PeerJ. 2023;11:e16142. Epub 20230925. doi: 10.7717/peerj.16142. PubMed PMID: 37780375;
- 747 PubMed Central PMCID: PMCPMC10538276.




Figure 1. Flowchart of participants' enrolment for the anti-SARS-CoV-2 antibody seroprevalence study in Superior Polytechnic School

Table I: Baseline characteristics of the study population

Variable	Value, N (%)
Overall	637 (100)
Age (years)	
Mean	23.20
Median	21
Range	18 - 63
Age group (years)	
[18-25]	546 (85.71)
(25-35]	38 (5.96)
(35-45]	26 (4.08)
(45-55)	12 (1.88)
(55-65]	6 (0.94)
Gender	(0.0.2)
Female	395 (62)
Male	235 (36.89)
Occupation	200 (00.07)
Students	563 (88.38)
Professors	22 (3.45)
TASO	1 1
Level of education	52 (8.16)
	AEO (70 64)
Bachelor degree	450 (70.64)
Master degree	117 (18.36)
PhD	20 (3.14)
others	18 (2.82)
Nationality	500 (0.1.50)
Senegalese	603 (94.66)
Others †	32 (5.03)
Ethnic groups	
Wolof	153 (24.02)
Fula	139 (21.82)
Serer	79 (12.40)
Jola	16 (2.50)
Malinke	17 (2.67)
Soninke	9 (1.41)
Mauri	7 (1.1)
Others †	18 (2.82)
Accommodation type	
Halls of residence	138 (21.67)
Family home	479 (75.19)
Family members	
Family members	
1-2	37 (5.81)
3-5	247 (38.77)
6-8	188 (29.51)
9 or plus	74 (11.61)
Matrimonial status	
Single	558 (87.60)
Married	60 (9.42)
Divorced	2 (0.31)
Smoker	` ′
Yes	10 (1.88)
No	538 (84.30)
Stopped > 1 year	10 (1.41)

Alcohol consumer	
Yes	21 (3.62)
No	554 (86.81)
Stopped > 1 year	3 (0.31)
BMI Categorized	
Underweight	69 (10.83)
Normal weight	240 (37.68)
Overweight /Obesity	53 (8.32)
Blood Group	
A-	9 (1.41)
A +	140 (21.98)
AB-	1 (0.15)
AB+	25 (3.92)
В-	5 (0.78)
B+	102 (16.01)
O-	24 (3.77)
O+	300 (47.08)
COVID-19 Vaccination	
Yes	221 (35.01)
No	365 (57.46)
Prefer not to say	51 (7.54)

N number; BMI Body Mass Indice; TASO technicians, administrative and service officers

[†] For nationality and ethnic group, others correspond to others of African nationality or ethnic group with very small numbers (maximum 5)






Figure 2: Compliance with Preventive measures recommended by authorities

Table II: Distribution of SARS-CoV-2 Ig M and G seropositive and seronegative individuals among the 637 participants enrolled.

Variable	IgM			IgG			
	Seronegative N (%)	Seropositive N (%)	p-value	Seronegative N (%)	Seropositive N (%)	p-valu	
Overall	593 (93.09)	44 (6.91)		51 (8)	576 (92)		
Age (years)							
Mean	23.06	25.16		22.4	23.28		
Median	21	21		21	21		
Range	18 - 63	18 - 59		18 - 47	18 - 63		
Age group			<0,001*			0,98	
[18-25]	516 (94.50)	30 (5.5)		53 (9.7)	493 (92.3)		
(25-35]	29 (76.31)	9 (23.69)		4 (10.53)	34 (89.47)		
(35-45]	24 (92.31)	2 (7.69)		2 (7.69)	24 (92.31)		
(45-55)	12 (100)	0 (0)		1 (8.33)	11 (91.67)		
(55-65]	4 (66.67)	2 (33.34)		0 (0)	6 (100)		
Gender			0.16	- (-)	()	0.89	
Female	373 (94.43)	22 (5.57)		37 (9.36)	358 (90.63)		
Male	213 (90.64)	22 (9.36)		24 (10.21)	211 (89.79)		
Occupation	220 (70102)	(>,00)	0.15	== (====)	222 (0505)	0.71	
Students	528 (93.78)	35 (6.22)	0.10	55 (9.77)	508 (90.23)	0.0 1	
Professors	19 (86.36)	3 (13.64)		1 (9.61)	21 (90.38)		
TASO	46 (88.46)	6 (11.54)		5 (4.54)	47 (95.45)		
Level of education	40 (00.40)	0 (11.54)	0.18	5 (4.54)	47 (55.45)	0.45	
	422 (04)	27 (6)	0.10	46 (10.22)	404 (89.78)	0.40	
Bachelor degree	423 (94)	27 (6)					
Master degree	105 (84.74)	12 (10.26)		12 (10.25)	105 (89.75)		
PhD	17 (85)	3 (15)		1 (5)	19 (95)		
others	16 (88.89)	2 (11.11)	0.00	0 (0)	18 (100)	0.20	
Nationality	E(E (00 00)	40 (6 61)	0.29	EC (0.0C)	E40 (00 E4)	0.30	
Senegalese	565 (93.39)	40 (6.61)		56 (9.26)	549 (90.74)		
Others †	26 (86.67)	4 (13.33)	0.00	5 (16.67)	25 (83.33)	0.15	
Ethnic groups		0 (5 - 5 - 5)	0.25			0.17	
Wolof	145 (94.77)	8 (5.23)		14 (9.15)	139 (90.85)		
Fula	128 (92.09)	11 (7.91)		11 (7.91)	128 (92.09)		
Serer	72 (91.14)	7 (8.86)		8 (10.13)	71 (89.87)		
Jola	14 (87.50)	2 (12.50)		0 (0)	16 (100)		
Malinke	16 (94.12)	1 (5.88)		3 (17.65)	14 (82.35)		
Soninke	9 (100)	0 (0)		3 (33.33)	6 (66.67)		
Mauri	7 (100)	0 (0)		0 (0)	7 (100)		
Others †	14 (77.78)	4 (22.22)		2 (11.12)	16 (88.88)		
Accommodation type			0.73			0.76	
Halls of residence	127 (92.03)	11 (7.97)		12 (8.69)	126 (91.31)		
Family home	447 (93.32)	32 (6.68)		48 (10.02)	431 (89.98)		
Family members			0.54			0.32	
1-2	36 (97.30)	1 (2.70)		2 (5.40)	35 (94.60)		
3-5	227 (91.90)	20 (8.10)		29 (11.75)	218 (88.25)		
6-8	176 (93.62)	12 (6.38)		20 (10.64)	168 (89.36)		
9 or plus	78 (90.70)	8 (9.30)		5 (5.81)	81 (94.19)		
Matrimonial Status			0.062			0.53	
Single	524 (93.9)	34 (6.1)		54 (9.68)	504 (90.32)		
Married	51 (85)	9 (15)		7 (11.67)	53 (88.33)		
Divorced	2 (100)	0 (0)		0 (0)	2 (100)		
Smoker	. ,	.,	0.08		, ,	0.16	
Yes	10 (100)	0 (0)		0 (0)	14 (100)		
No	503 (93.49)	35 (6.51)		57 (9.69)	531 (90.31)		
Stopped > 1 year	8 (80)	2 (20)		0 (0)	10 (100)		
Alcohol consumer	- (00)	_(=5)	0.12	- (0)	23 (200)	0.038	
Yes	19 (90.48)	2 (9.52)	0120	1 (4.76)	20 (95.24)	31300	

No	516 (93.14)	38 (6.86)		51 (9.20)	503 (90.80)	
Stopped > 1 year	3 (100)	0 (0)		1 (33.34)	2 (66.66)	
BMI Categorized			0.089			0.55
Underweight	67 (97.10)	2 (2.90)		6 (8.70)	63 (91.30)	
Normal weight	224 (93.33)	16 (6.67)		28 (11.67)	212 (88.33)	
Overweight /Obesity	46 (86.79)	7 (11.36)		8 (15.09)	45 (84.91)	
Blood Group			0.95			0.094
A-	8 (88.89)	1 (11.11)		1 (11.11)	8 (88.89)	
A+	131 (93.57)	9 (6.43)		14 (10)	126 (90)	
AB-	1 (100)	0 (0)		1 (100)	0 (0)	
AB+	24 (96)	1 (4)		3 (12)	22 (88)	
B-	4 (80)	1 (20)		0 (0)	5 (100)	
B+	94 (92.16)	8 (7.84)		7 (6.86)	95 (93.14)	
O-	22 (91.67)	2 (8.33)		1 (4.17)	23 (95.83)	
O+	279 (93)	21 (7)		29 (9.67)	271 (90.33)	
COVID-19 Vaccination			0.624			< 0.0001
Yes	203 (91.85)	18 (8.15)		7 (3.17)	214 (96.83)	
No	340 (95.15)	25 (6.85)		49 (13.42)	316 (86.58)	
Prefer not to say	50 (98.04)	1 (1.96)		5 (9.8)	46 (90.2)	

^{*}Statistics were calculated without missing values. Missing values were excluded from the analysi

Table III. Distribution of Sars-Cov-2 Ig M and G seropositive and seronegative according to preventive measures

	IgM			IgG		
	Seronegative n (%)	Seropositive n (%)	p- value	Seronegative n (%)	Seropositive n (%)	p- value
Wearing masks			0.17			0.73
Always/Often	183 (91.04)	18 (8.96)		19 (9.45)	182 (90.55)	
Sometimes/Rarely	355 (93.42)	25 (6.58)		38 (10)	342 (90)	
Never	30 (100)	0 (0)		4 (13.33)	26 (86.67)	
Kept a physical distance of 2 m		,	0.35			0.33
Always/Often	110 (94.83)	6 (5.17)		8 (6.90)	108 (93.10)	
Sometimes/Rarely	277 (91.42)	26 (8.58)		31 (10.23)	272 (89.77)	
Never	161 (94.15)	10 (5.85)		21 (12.28)	150 (87.72)	
Wash hands with hydroalcoholic or with soap and water		, ,	0.105			0.599
Always/Often	451 (93.96)	29 (6.04)		51 (10.62)	429 (89.38)	
Sometimes/Rarely	108 (88.52)	14 (11.48)		10 (8.20)	112 (91.80)	
Never	4 (100)	0 (0)		0 (0)	4 (100)	
Number of visits received in the last 15 days			0.583			0.971
0-2	205 (93.61)	14 (6.39)		23 (10.50)	196 (89.50)	
3-8	188 (92.16)	16 (7.84)		21 (10.29)	183 (89.71)	
≥9	146 (94.80)	8 (5.20)		15 (9.74)	139 (90.26)	
Number of visits made in the last 15 days			0.008*			0.946
0-2	373 (94.20)	23 (5.81)		41 (10.35)	355 (89.65)	
3-8	109 (87.20)	16 (12.80)		12 (9.60)	113 (90.40)	
≥9	73 (97.33)	2 (2.67)		7 (9.33)	68 (90.67)	
Public transport use per day over the last 15 days			0.878	, ,		0.668
0-2	419 (92.9)	32 (7.1)		44 (9.75)	407 (90.25)	
3-5	105 (92.92)	8 (7.1)		14 (12.39)	99 (87.61)	
≥9	33 (91.67)	3 (8.33)		3 (8.33)	33 (91.67)	
Participation in a social event in the last 15 days			0.589			0.289
0-2	423 (92.76)	33 (7.24)		51 (11.18)	405 (88.82)	
3-8	79 (90.80)	8 (9.20)		5 (5.75)	82 (94.25)	
≥9	44 (95.65)	2 (4.35)		4 (8.70)	42 (91.30)	

Significant values are in bold.

Table IV: Multiple logistic regression of sociodemographical risk factors affecting seropositivity

	IgM				IgG			
Variable	Univariate OR (95% CI)	p- value	Multivariate OR (95% CI)	p- value	Univariate OR (95% CI)	p- value	Multivariate OR (95% CI)	p- value
Age	1.034 [0.99 - 1.06]	0.055	0.971 [0,74 -1,21]	0,808	1.023 [0.98 – 1.081]	0.345	0.974 [0.89 – 1.071]	0.573
Gender	1.75 [0.943 - 3.25]	0.073	0.776 [0,10 – 4.6]	0.791	0.906 [0.53 - 1.578]	0.728	0.913 [0.52 - 1.62	0.757
Occupation	1.652 [0.92 – 2.72]	0.065	1.345[0,06 – 22.03]	0.834	1.26 [0.69 – 2.75]	0.508	2.545 [0.60 – 15.33]	0.250
Level of education	1.526 [0.91 – 2.47]	0.095	1.709 [0.31 – 9.47]	0.532	0.973 [0.61 – 1.61]	0.911	0.917 [0.48 – 1.73]	0.790
Nationality			0.074 [0.003 – 2.21]	0.083	1.96 [0.64 – 4.93]	0.186	2.286 [0.49 – 7.82]	0.225
Ethnic groups	0.985 [0.86 – 1.13]	0.826	0.723 [0.49 – 0.96]	0.046 *	0.95 [0.84 - 1.07]	0.426	0.967 [0.85 – 1.095]	0.6
Place of residence	0.995 [0.72 – 1.23]	0.740	0.562 [0.17 – 1.24]	0.23	0.998 [0.80 – 1.27]	0.992	0.981 [0.74 – 1.32]	0.894
Accommodatio n type	1.21 [0.57 – 2.40]	0.60	4.209 [0.91 – 21.62)	0.067	1.17 [0.62 – 2.37]	0.643	0.924 [0.41 – 2.23]	0.854
Family members	1.133 [0.77 – 1.66]	0.522	1.849 [0.78 – 4.78]	0.175	1.138 [0.81 – 1.6]	0.452	1.234 [0.83 – 1.85]	0.296
Maritus status	2.399 [1.08 – 4.87]	0.021 *	4.44 [0.28 – 54.32]	0.235	1.02 [0.47 – 2.68]	0.956	1.135 [0.43 – 3.95]	0.818
Smoking	1.004 [0.21 – 2.48]	0.995	2.897 [0.087 – 36.8]	0.457				
Alcohol	1.064 [0.18 - 3.17]	0.926	2.06 [0.066 – 30.84}	0.622	0.835 [0.32 – 3.25]	0.747		
BMI Categorized	2.015 [1.12 – 3.56]	0.016 *	1.215 [0.39 – 3.73]	0.729	0.785 [0.49 – 1.29]	0.329	0.718 [0.43 – 1.21]	0.206
Blood Group	1.011 [0.89 – 1.152]	0.861	1.049 [0.786 – 1.47]	0.235	1.023 [0.91 – 1.14]	0.679	0.988 [0.86 – 1.24]	0.842
Vaccination Status	1.206 [0.63 – 2.25]	0.560	0.428 [0.08 – 1.89]	0.285	4.741 [2.25 – 11.65]	<0.00 1 *	2.714 [0.59 – 48.48]	0.325

OR odds ratio. Signifcant values are in bold.

Table V: Multiple logistic regression of preventive measures affecting seropositivity

	IgM		IgG		
Variable	Univariate OR (95% CI)	p- value	Univariate OR (95% CI)	p- value	
Wearing masks	0.796 [0,5893 - 1,073]	0.134	0.966 [0.74 – 1.25]	0.793	
Failure to respect the 2m distance	0.980 [0,7380 - 1,278]	0.886	1.229 [0.96 – 1.59]	0.108	
Number of visits received in the last 14 days	0.901 [0.701 – 1.15]	0.404	1.002 [0.82 – 1.23]	0.984	
Number of visits made in the last 14 days					
Wash hands with hydroalcoholic	0.854 [0.62 – 1.17]	0.327	0.891 [0.68 – 1.17]	0.405	
Public transport use per day over the last 15 days	1.043 [0.75 – 1.40]	0.793	1.072 [0.82 – 1.441]	0.630	
Participation in a social event in the last 15 days	0.952 [0.71 – 1.24]	0.734	1.094 [0.86 – 1.420]	0.473	